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Coexistence
Interferon beta 1-aCoexistence of multiple sclerosis (MS) with other autoimmune diseases has been attributed to
common background genetic or environmental factors. This study presents development of
rheumatoid arthritis (RA) during treatment of MS. The MS was confirmed by the Mc Donald
criteria and the diagnosis of RA was confirmed by the ACR/EULAR criteria. A 35 years old
women with 9 years of MS who was receiving interferon beta 1-a (INF) for 7 years and who
did not respond to conventional therapy of RA over 8 months developed clinical manifestations
of RA. But a rapid response was observed after discontinuation of INF. These findings suggest
a possible contribution of INF in the development of RA.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Patients with autoimmune diseases such as multiple sclerosis
(MS) have greater susceptibility for development of another
autoimmune disease [1–3]. This issue is important, becauseoccurrence of another condition, in particular a musculoskele-
tal disease in patients with previous neurologic lesions due to
MS, increases the risk of disability. Occurrence of rheumatoid
arthritis (RA) in MS may indicate coincidence of two condi-
tions or a consequence of medical treatment. We report a case
of MS who developed RA during treatment with interferon
beta 1-a (INF) and response to conventional therapy was
observed only after discontinuation of INF.
Case presentation
A thirty-five years old woman was admitted to our hospital
with polyarthritis involving wrists, right knee, metatarsal
(MTP) and proximal interphalangeal (PIP) joints, morning
612 S.M.M. Hojjati et al.stiffness to our hospital. Joint involvement and pain started
two years prior to admission with an initial presenting mani-
festation of inflammatory arthritis [4,5]. Serologic assessment
for rheumatoid factor (RF) and anti-cyclic citrolinated peptide
antibody (Anti-CCP) was negative at that time. Treatment was
started with non-steroidal anti-inflammatory drugs (NSAIDs)
and subsequently with hydroxychloroquine and low dose pred-
nisolone. The patient had history of MS for 9 years and the
diagnosis was confirmed by the McDonald criteria based on
clinical manifestations with compatible brain lesions on mag-
netic resonance imaging. Treatment with intramuscular inter-
feron beta-1a (INF) was started once a week and the
patients achieved remission and continued maintenance treat-
ment. Joints manifestations occurred 7 years after occurrence
of MS which continued over the follow-up period and pro-
gressed to symmetrical polyarticular arthritis with synovitis
and joints swelling. Clinical examination revealed joint pain
and swelling in all involved joints and anti-cyclic citrulinated
peptide antibody (Anti-CCP) and rheumatoid factor (RF)
were positive. A definite diagnosis of RA was confirmed
according to 2010 ACR/EULA criteria after excluding other
inflammatory arthritis [4,5]. Methotrexate (MTX) 10 mg
weekly was added to hydroxychloroquine 200 mg and pred-
nisolone 5 mg/daily and MS treatment with INF continued.
Over the 8-month follow-up period, arthritis deteriorated
and clinical examination revealed severe polyarthritis involving
PIP, MTP, wrists, knee and MTP joints in spite of taking
15 mg MTX per week, prednisolone 5 mg daily and hydroxy-
chloroquine 400 mg/daily. Further clinical examination and
laboratory tests ruled out other inflammatory arthritis and
HLA DRB1*04, *10 test was positive. The dosage of pred-
nisolone was increased to 10 mg daily and treatment of MS
changed to glatiramer acetate at 3 subcutaneous injections
per week. The patients responded to the treatment and the
results of the latest follow-up examination two years after
beginning of RA showed remission of both RA and MS.
Discussion
This study indicates development of RA in women with previ-
ously diagnosed MS under treatment with INF. The diagnosis
of RA was confirmed based on the ACR/EULAR classifica-
tion criteria and exclusion of other inflammatory arthritis by
appropriated clinical and laboratory tests. Although radio-
graphic erosions suggestive of RA have not been investigated,
nonetheless, seropositivity for both RF and ACCP, HLA
DRB1*04, *10 positivity, symmetrical involvement of the
small joints of upper and lower limb joints provide further sup-
porting data in favour of RA.
The association of MS and RA has been reviewed by Tous-
sirot et al. in 14 cases (85.7% females) with coexistent diseases
in the majority of patients and the MS occurred prior to devel-
opment of RA and had no influence on the course of RA. The
course of RA in 8 patients was progressive and the remaining
patients had relapsing remitting courses. None of these
patients received INF [1].
Coexistence of MS and juvenile chronic arthritis has been
also reported [6,7]. Mpofu et al., reported a coincidental
occurrence of RA in a 59 years old man with longstanding
MS. Definite diagnosis with compatible features of RA waspossible only after four years of follow-up period. The patient
had not received INF [2,3].
Patients with MS are more prone for development of sec-
ond autoimmune disease. This has been attributed to genetic
background or contribution of environmental factors such as
viruses [8].
Several mechanisms including molecular mimicry, dual T
cell receptors (TCRs) and chimeric TCRs have been pro-
posed for development of autoimmune diseases. Initiation
of autoimmune diseases by infectious agents is attributed
to dual activity of the T cells [9]. Both genetic and environ-
mental factors such as viruses have been incriminated for
development of autoimmune diseases including MS and RA
[8,9]. Th17 cells and IL17 have an important role in the host
defence against extracellular fungal and bacterial pathogens
and play a critical role in the pathogenesis of multiple
inflammatory and autoimmune disorders [10] particularly
immune mediated inflammatory arthritis such as RA,
spondyloarthropathies, MS, psoriatic arthritis and SLE
[11,12]. Innate-derived IL-17 constitutes a major element in
the altered immune response against self-antigens or perpet-
uation of inflammation [13]. These cells have a crucial role
in the pathogenesis of autoimmune demyelinating diseases
in both mice and humans [14]. In RA the level of IL-17 in
the synovial fluid correlates with disease severity and anti-
IL-17 therapy is effective treatment of RA [15,16] Depending
on the microenvironment, Th17 cells can alter their differen-
tiation programme to either protective or pro-inflammatory
pathogenic cells [10].
In MS patients treatment with interferon beta-1a can
increase TGF-b1 [6]. It was shown that in both latent and
active RA, the level of TGF-b1 in synovial fluid is increased
[17]. In addition, rapid response to treatment after discontinu-
ation of INF suggests an association between INF therapy and
development of RA.
Development of juvenile chronic arthritis during treatment
of MS has been reported [3]. This issue may suggest alteration
in Th17 cells differentiation programme by INF [15] However,
regarding a prolonged interval period between beginning of
MS and development of RA, coincidence occurrence of two
diseases cannot be ignored. This issue requires further
studies.
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